Zhang Zheng, Zhang Linlei, Ding Yuchuan, Han Zhao, Ji Xunming
1Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
2Department of Neurology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Aging Dis. 2018 Jun 1;9(3):507-522. doi: 10.14336/AD.2017.0628. eCollection 2018 Jun.
Ischemic stroke is a major cause of death and disability globally, and its incidence is increasing. The only treatment approved by the US Food and Drug Administration for acute ischemic stroke is thrombolytic treatment with recombinant tissue plasminogen activator. As an alternative, therapeutic hypothermia has shown excellent potential in preclinical and small clinical studies, but it has largely failed in large clinical studies. This has led clinicians to explore the combination of therapeutic hypothermia with other neuroprotective strategies. This review examines preclinical and clinical progress towards developing highly effective combination therapy involving hypothermia for stroke patients.
缺血性中风是全球范围内导致死亡和残疾的主要原因，且其发病率正在上升。美国食品药品监督管理局批准的用于急性缺血性中风的唯一治疗方法是使用重组组织型纤溶酶原激活剂进行溶栓治疗。作为一种替代方法，治疗性低温在临床前和小型临床研究中已显示出优异的潜力，但在大型临床研究中大多失败了。这促使临床医生探索将治疗性低温与其他神经保护策略相结合。本综述探讨了在为中风患者开发涉及低温的高效联合疗法方面的临床前和临床进展。
